SQZ Biotechnologies to Present at Jefferies Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Jefferies Healthcare Conference on June 8, in New York, NY. Presentation time and webcast information is available below.

PRESENTATION DETAILS

Wednesday, June 8
Jefferies Healthcare Conference
2:30-2:55 p.m. ET
Webcast

Conference webcast details and the company’s most recent corporate overview presentation will be available on the Investors section of the SQZ website. Replay will be available for 90 days.

Based on guidance from the SEC, investors should note that the company may announce future healthcare conference presentations on the Events & Presentations page of the Investor Relations section of its corporate website, investors.sqzbiotech.com. It is possible that the information posted there could be deemed to be material information.

About SQZ Biotechnologies

SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world. The company has active programs in oncology, autoimmune and infectious diseases, as well as additional exploratory initiatives to support future pipeline growth. SQZ’s proprietary Cell Squeeze® technology can deliver multiple biological materials into many cell types, offering the ability to engineer a broad range of potential therapeutics. With clinical production timelines already under 24 hours, the company has the potential to enable broader patient accessibility through point-of-care manufacturing implementation across multiple therapeutic programs. Our approach could also improve a patient’s treatment journey with no planned hospitalization or preconditioning treatment. The company’s first therapeutic efforts seek to generate target-specific immune responses, both through activation for the treatment of solid tumors and infectious diseases, and by immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

Investor:
Mike Kaiser
michael.kaiser@sqzbiotech.com
857-760-0398

Media:
John Lacey
john.lacey@sqzbiotech.com
781-392-5514